Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesWBO:EWLS -0.49%95 Cash-to-Debt is 6.04 as of Jun. 2026, which is 192% above its 10-year median of 2.07. GuruFocus rates WBO:EWLS with a GF Score™ of 95/100 and a GF Value™ of €82.41 (Fairly Valued). The stock has 3 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 69.24% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Edwards Lifesciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 6.04.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Edwards Lifesciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Edwards Lifesciences's Cash-to-Debt or its related term are showing as below:
WBO:EWLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.08 Med: 2.07 Max: 6.29
Current: 6.04
During the past 13 years, Edwards Lifesciences's highest Cash to Debt Ratio was 6.29. The lowest was 1.08. And the median was 2.07.
WBO:EWLS's Cash-to-Debt is ranked better than 69.24% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs WBO:EWLS: 6.04
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Edwards Lifesciences Cash-to-Debt Related Terms
Edwards Lifesciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WBO:EWLS vs BSX, DXCM, GEHC: Cash-to-Debt Comparison
For the Medical Devices subindustry, Edwards Lifesciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (WBO:EWLS) has a Cash-to-Debt of 6.04 as of Jun. 2026. This is 192% above median its historical median of 2.07. Over the past decade, Edwards Lifesciences' Cash-to-Debt has ranged from 1.08 to 6.29. According to the industry distribution chart, Edwards Lifesciences ranks #259 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 30.8%.
Is Edwards Lifesciences' Cash-to-Debt too high?
Edwards Lifesciences' current Cash-to-Debt of 6.04 is 192% above median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 6.29. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Edwards Lifesciences' value of 6.04 is 269.4% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #259 out of 842 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Cash-to-Debt compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #259 out of 842 companies for Cash-to-Debt. This puts Edwards Lifesciences in the upper half of its industry. The industry median Cash-to-Debt is 1.64. Edwards Lifesciences' value of 6.04 is 269.4% above this benchmark. Historically, Edwards Lifesciences' own Cash-to-Debt has ranged from 1.08 to 6.29 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 1.64, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Cash-to-Debt of 6.04 is 269.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Cash-to-Debt is 6.04, which is 192% above median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €82.41, compared to a current price of €77.00 — trading 6.6% below its estimated fair value. The current Cash-to-Debt is 6.04, which is 192% above median its 10-year median of 2.07 and 269.4% above the Medical Devices & Instruments industry median of 1.64. Edwards Lifesciences' overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current Cash-to-Debt is 6.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of €77.00 is trading 6.6% below its estimated GF Value™ of €82.41.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for WBO:EWLS:
Cash-to-Debt: 6.04 (192% above median its 10-year median of 2.07)
GF Value™: €82.41 vs. price of €77.00 (6.6% below fair value)
Industry Position: 269.4% above the Medical Devices & Instruments median (#259 of 842)
No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
95GF Score
Get the complete analysis for WBO:EWLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:EWLS has been successfully added to your 
